A phase II clinical trial of sorafenib in androgen-independent prostate cancer by Dahut William L, Scripture Charity, Posadas Edwin, Jain Lokesh, Gulley James L, Arlen Philip M, Wright John J, Yu Yunkai, Cao Liang, Steinberg Seth M, Aragon-Ching Jeanny B, Venitz J├╝rgen, Jones Elizabeth, Chen Clara C, Figg William D in Clinical cancer research : an official journal of the American Association for Cancer Research (2008).

[PMID: 18172272] PubMed


To determine if sorafenib is associated with a 4-month probability of progression-free survival, which is consistent with 50%, as determined by clinical, radiographic, and prostate-specific antigen (PSA) criteria in patients with metastatic androgen-independent prostate cancer (AIPC).

[ hide abstract ]

Discussed In Paper


Rx Annotations

No dosing information annotated.